JPH061723A - Renal function improving medicine - Google Patents

Renal function improving medicine

Info

Publication number
JPH061723A
JPH061723A JP4180309A JP18030992A JPH061723A JP H061723 A JPH061723 A JP H061723A JP 4180309 A JP4180309 A JP 4180309A JP 18030992 A JP18030992 A JP 18030992A JP H061723 A JPH061723 A JP H061723A
Authority
JP
Japan
Prior art keywords
extraction
extract
leaves
tea
renal function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4180309A
Other languages
Japanese (ja)
Inventor
Kunihiko Kato
邦彦 加藤
Masatoshi Nakano
昌俊 中野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RUIBOSUTEII JAPAN KK
Original Assignee
RUIBOSUTEII JAPAN KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RUIBOSUTEII JAPAN KK filed Critical RUIBOSUTEII JAPAN KK
Priority to JP4180309A priority Critical patent/JPH061723A/en
Publication of JPH061723A publication Critical patent/JPH061723A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To provide a medicine capable of quickly improving/curing, without side effects, nephropathy (esp. oliguric nephropathy) of mammals including humans through its taking. CONSTITUTION:The medicine (diuretic) containing, as active ingredient, an extract of Asparasus linealis. For the extraction, the leaves or stems of the above plant are extracted with water and/or an organic solvent and the extraction solvent is distilled off the resultant extract; or, such leaves or stems may be ground; or extraction may be carried out in a similar way as with conventional Japanese tea, Chinese tea, or black tea.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、マメ科に属するアスパ
ラサス・リネアリスの含有成分を有効成分とする腎臓機
能改善治療、利尿剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a renal function-improving treatment and a diuretic agent containing an active ingredient of Aspalathus linealis belonging to the legume family.

【0002】[0002]

【従来の技術】従来より,乏尿性腎臓疾患に対しては、
アルダクトン(大日本製薬社)などのアルドステロン拮
抗薬、ラシックス(ヘキスト社)などのループ利尿薬、
あるいはダイアモックス(武田薬品社)などの炭酸脱水
素酵素阻害薬などの利尿剤が知られている。
2. Description of the Related Art Conventionally, for oliguric kidney disease,
Aldosterone antagonists such as Aldacton (Dainippon Pharmaceutical Co., Ltd.), loop diuretics such as Lasix (Hoechst),
Alternatively, diuretics such as carbonic anhydrase inhibitors such as Diamox (Takeda Pharmaceutical Company) are known.

【0003】[0003]

【発明が解決しようとする課題】しかし、利尿剤はN
a,K輸送担体を阻止したり、炭酸脱水素酵素を阻害し
たりあるいはアルドステロンに対する拮抗作用をする人
工合成化合物を用いているために、副作用もあり一時的
な薬剤としては有効であるが、長期間使用することは不
可能である。
However, the diuretic is N
It is effective as a temporary drug because it has side effects because it uses an artificial synthetic compound that blocks a, K transport carriers, inhibits carbonic anhydrase, or antagonizes aldosterone. It cannot be used for a period of time.

【0004】また、腎臓疾患は従来よりナトリウム摂取
を制限する食事療法が行なわれているが、患者の食生活
における味の変化の為に、ナトリウム摂取を制限する食
事療法では効果が薄いか長時間を要するため、十分な効
果を得るには難しい。
[0004] For renal diseases, a diet therapy that restricts sodium intake has been conventionally performed. However, due to a change in taste in patients' diets, a diet therapy that restricts sodium intake is less effective or long-term. Therefore, it is difficult to obtain a sufficient effect.

【0005】本発明は、前記課題を解決し、腎臓疾患、
特に急性腎炎など乏尿性腎疾患に有効な症状の改善治療
剤を提供することを目的とする。
The present invention solves the above-mentioned problems and improves kidney disease,
In particular, it is an object of the present invention to provide a therapeutic agent for improving symptoms which is effective for oliguric renal diseases such as acute nephritis.

【0006】そこで、本発明者らは、前記目的を達成す
るために鋭意研究を重ねた結果、マメ科に属するアスパ
ラサス・リネアリス抽出物が、急性腎炎などの乏尿性腎
臓疾患に対し優れた効果を有し、かつ副作用がなく安全
に各種皮膚疾患等を改善できるとの知見を得て本発明を
完成した。
[0006] Therefore, as a result of intensive studies for achieving the above-mentioned object, the present inventors have found that Asparasus linealis extract belonging to the legume family was excellent against oliguric kidney diseases such as acute nephritis. The present invention has been completed based on the finding that it has effects and can safely improve various skin diseases without side effects.

【0007】本成分の有効成分は、アスパラサス・リネ
アリスの抽出液からなり、抽出法としては、アスパラサ
ス・リネアリスの葉または茎を水及び/または有機溶媒
で抽出し、該抽出液より抽出溶媒を留去する方法、また
はアスパラサス・リネアリスの葉または茎を粉砕するこ
とによって得ることができる。また、通常の日本茶、中
国茶、紅茶などの製法と同様に抽出してもよい。
The active ingredient of this component consists of an extract of Aspalathus linealis. As the extraction method, leaves or stems of Aspalathus linealis are extracted with water and / or an organic solvent, and the extraction solvent is extracted from the extract. Can be obtained by distilling off or by crushing leaves or stems of Aspalathus linealis. In addition, it may be extracted in the same manner as in the production method of ordinary Japanese tea, Chinese tea, black tea and the like.

【0008】水で抽出する場合には、アスパラサス・リ
ネアリスの50〜1000倍の水を加え、90〜100
度で5〜30分程度抽出するのが好ましい。また、通常
の茶と同様にするときは、アスパラサス・リネアリスの
乾燥葉の50〜1000倍の水を加え、90〜100度
で5〜30分間程度沸騰させ抽出液を得る。
In the case of extraction with water, 50 to 1000 times as much water as Aspalathus linealis is added, and 90 to 100 is added.
It is preferable to extract for about 5 to 30 minutes. Moreover, when making it the same as normal tea, 50 to 1000 times as much water as dry leaves of Aspalathus linealis is added, and the extract is boiled at 90 to 100 degrees for about 5 to 30 minutes to obtain an extract.

【0009】有機溶媒の具体例としては、メタノール、
エタノール、アセトン等が挙げられ、抽出にあたっては
温時抽出等慣用手段を用いることができる。また、抽出
液の分離も、デカンテーションや遠心分離等の慣用手段
を用いることができる。
Specific examples of the organic solvent include methanol,
Ethanol, acetone and the like can be mentioned, and conventional means such as warm extraction can be used for extraction. Further, for the separation of the extract, conventional means such as decantation or centrifugation can be used.

【0010】抽出溶媒の留去も凍結乾燥等の慣用手段を
用いることができる。また、アスパラサス・リネアリス
そのものを粉砕し、微小化・粉末化して用いることもで
きる。
A conventional means such as freeze-drying can be used for distilling off the extraction solvent. In addition, Aspalathus linealis itself can be crushed, and can be used after being miniaturized and powdered.

【0011】本組成物は、有効成分を生理学的に許容さ
れうる担体、賦形剤、結合剤、希釈剤と混合し、たとえ
ば顆粒剤、粉剤、硬カプセル剤、軟カプセル剤、塗布
剤、シロップ、坐剤、注射剤として経口または非経口的
に、または、混合してそのまま溶液、粉末顆粒、錠剤、
乳剤、ゼリー状など任意の形態で単独投与、濃縮液を利
用、または他の飲食物に混合して飲食することもでき
る。
The composition is prepared by mixing the active ingredient with physiologically acceptable carriers, excipients, binders and diluents, for example granules, powders, hard capsules, soft capsules, coatings and syrups. , Suppositories, orally or parenterally as injections, or as a mixture as it is, solutions, powder granules, tablets,
It can be administered alone in any form such as an emulsion or jelly, can be used as a concentrated solution, or can be mixed with other foods and drinks.

【0012】投与量は、対象となる疾患の種類、程度に
より異なるが、飲料としてヒトが常用する場合には、1
〜5g乾燥葉/1溶液を100ml〜2000ml/日
飲食するのが好ましい。ペットなどの動物に与える場合
には2ml/kg体重〜30ml/kg体重与えるのが
好ましい。また、凍結乾燥顆粒粉末のときは、それぞれ
1g〜10g/日与えるのが好ましい。
The dose varies depending on the kind and degree of the target disease, but in the case where humans regularly use it as a drink, the dose is 1
It is preferable to eat and drink ~ 5 g dry leaf / 1 solution at 100 ml-2000 ml / day. When given to animals such as pets, it is preferable to give 2 ml / kg body weight to 30 ml / kg body weight. In the case of freeze-dried granule powder, it is preferable to give 1 g to 10 g / day, respectively.

【0013】アスパラサス・リネアリスは、ラットに対
する急性毒性試験で死亡例は皆無であり、生化学血液検
査および病理組織学的検査においても異常が認められな
かった。
[0013] Aspalathus linealis showed no death in an acute toxicity test in rats, and no abnormality was observed in biochemical blood tests and histopathological tests.

【0014】[0014]

【効果】本発明は、ヒトを含む哺乳動物の腎臓疾患、特
に乏尿性腎臓疾患を飲食等により副作用無く、迅速に改
善す治療ることができる。
[Effect] The present invention can treat renal diseases of mammals including humans, in particular, oliguric renal diseases, which can be rapidly improved by eating or drinking without side effects.

【0015】[0015]

【実施例】【Example】

製造例 採取したアスパラサス・リネアリスの葉(茎つき)を、
5mm長に切断後、ローリング、酵素醗酵、天日乾燥の
工程を経て乾燥葉とする。乾燥葉4gを水1.5リット
ルで15分間沸騰させ抽出液を得た。
Production example Collected Aspalathus linealis leaves (with stem)
After cutting to a length of 5 mm, dried leaves are subjected to the steps of rolling, enzyme fermentation, and sun drying. 4 g of dried leaves were boiled with 1.5 liters of water for 15 minutes to obtain an extract.

【0016】実施例 製造例で得たアスパラサス・リネアリス抽出液を腎機能
が低下し顔面に浮腫のあるパネラー5名に一日コップ1
〜5杯飲ませ、腎機能の改善を調べた。その結果、4名
において飲み始めてすぐに利尿作用により尿量も多くな
り、1〜2週間で顔面の浮腫もあらわれなくなり、疲れ
なくなった。
Example 1 cup of the Aspalathus linealis extract obtained in the production example per day for 5 panelists with reduced renal function and edema on the face
~ 5 cups were given and examined for improvement in renal function. As a result, in 4 persons, the amount of urine increased due to a diuretic effect immediately after starting drinking, and facial edema did not appear in 1 to 2 weeks, and the body became tired.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 アスパラサス・リネアリス抽出物を有効
成分とする腎臓機能改善治療剤。
1. A therapeutic agent for improving renal function, comprising an Aspalathus linealis extract as an active ingredient.
【請求項2】 アスパラサス・リネアリス抽出物を有効
成分とする利尿剤。
2. A diuretic containing an Aspalathus linealis extract as an active ingredient.
JP4180309A 1992-06-15 1992-06-15 Renal function improving medicine Pending JPH061723A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4180309A JPH061723A (en) 1992-06-15 1992-06-15 Renal function improving medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4180309A JPH061723A (en) 1992-06-15 1992-06-15 Renal function improving medicine

Publications (1)

Publication Number Publication Date
JPH061723A true JPH061723A (en) 1994-01-11

Family

ID=16080963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4180309A Pending JPH061723A (en) 1992-06-15 1992-06-15 Renal function improving medicine

Country Status (1)

Country Link
JP (1) JPH061723A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003299456A (en) * 2002-04-09 2003-10-21 Masayoshi Iwahara Epidermal powder of asparasus linearis or asparasus cederbergensis and method for producing the same
CN104189790A (en) * 2014-09-30 2014-12-10 河南亚卫动物药业有限公司 Traditional Chinese medicine composition for treating cow conception edema and preparation method thereof
CN104225027A (en) * 2014-09-30 2014-12-24 三穗县耿德发诊所 Medicament for treating swelling and preparation method of medicament

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003299456A (en) * 2002-04-09 2003-10-21 Masayoshi Iwahara Epidermal powder of asparasus linearis or asparasus cederbergensis and method for producing the same
CN104189790A (en) * 2014-09-30 2014-12-10 河南亚卫动物药业有限公司 Traditional Chinese medicine composition for treating cow conception edema and preparation method thereof
CN104225027A (en) * 2014-09-30 2014-12-24 三穗县耿德发诊所 Medicament for treating swelling and preparation method of medicament

Similar Documents

Publication Publication Date Title
US5932624A (en) Vitamin supplement composition
KR101687982B1 (en) Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof
CA2871478C (en) Pleuropterus multiflorus extract and dipsacus asperoides extract for stimulating the secretion of insulin-like growth factor and promoting bone structure growth, and method for preparing same
WO2007007993A1 (en) Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract
US6984405B1 (en) Compositions for inducing secretion of insulin-like growth factor-1
JPH05246866A (en) Agent for stimulating cerebral metabolism and for improving cerebral function
KR100678519B1 (en) A composition comprising the extract of Semisulospira libertine Sulfur Fed Duck Ulmus devidiana Pine Pollen Powder Acer tegmentosum Maxim. Bamboo Salt Artemisia capillaries Platycodon Grandiflorum Rhynchosiavolubilis for the prevention and treatment of fatty liver
EP1583547B1 (en) Anti-obesity ingredients from medicinal plants and their composition
KR20160042521A (en) Composition for Promoting Osteogenesis and Composition for Preventing or Treating Hyperlipidemia
JP3502072B2 (en) Health food composition for protecting liver (Healthy food composition for protecting hepatic)
JPH06263648A (en) Promoter for lowering alcohol in body and its metabolite and refrigerant in mouth
JPH061723A (en) Renal function improving medicine
KR100376305B1 (en) Healthy food composition for protecting hepatic
JPH0840923A (en) Nutrient-supplying agent
KR20100132101A (en) Compositions for preventing and treating allergy comprising of fruits of prunus davidiana fr
RU2332866C2 (en) Dietary supplement "perstevit"
JPH01299224A (en) Promoter of cholesterol excretion, use and mixture thereof
JP4534003B2 (en) Health food with antiallergic action
JP3167777B2 (en) Antiviral, antibacterial and bactericide
JP2724524B2 (en) Constipation improvement / treatment agent
CN101143203A (en) Compound oral liquid with liver-protecting and stomach-nourishing function
US20040146468A1 (en) Oral compositon comprising an extract from the bark of albizzia myrioplylla
JPH01304861A (en) Production of dried powder of earthworm
KR102281950B1 (en) Composition for reducing toxicity containing corn silk extract
JPH069357A (en) Agent for removing body smell and bad smell of excreta